Pembrolizumab plus vorinostat is highly active in Hodgkin lymphoma, including patients refractory to prior PD-1 blockade.
Matthew G MeiLu ChenJames K GodfreyJoo Y SongColt A EgelstonL Elizabeth Elizabeth BuddeSaro H ArmenianLiana NikolaenkoMary NwangwuWeihua GuoLei GaoPeter LeeRobert W ChenShari DanielsNeena KennedyLacolle PetersJasmine ZainSteven T RosenStephen J FormanLeslie L PopplewellLarry W KwakAlex F HerreraPublished in: Blood (2023)
Pembrolizumab and vorinostat was well-tolerated with a high ORR rate in RR cHL including in anti-PD1-refractory disease.